ABCG2 and non-small cell lung carcinoma: It has been reported that ABCG2 expression is increased in non-small cell lung cancer lines showing resistance to gefitinib, suggesting that overexpression of this transporter is one of the mechanisms underlying resistance to EGFR TKIs [10].